CTRI/2022/01/039242尚未招募不适用
Retrospective and prospective observational study toevaluate the outcome of patients with metastatic hormone-positivebreast cancer treated with a combination of chemotherapy andendocrine therapyâ€
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 1,000
- 试验地点
- 1
- 主要终点
- 1.To analyze the overall survival (OS) of included patients
研究概览
简要总结
To determine the outcome of metastatic breast cancer patients with ER and/or PR positive and HER2 negative tumors who have been treated with a combination of endocrine and chemotherapy
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18.00 Year(s) 至 99.00 Year(s)（—）
- 性别
- All
入选标准
- •All patients above 18 yrs who have ER and/or PR positive and HER2 negative metastatic breast cancer and who have received a combination of chemotherapy and endocrine therapy between January 2016 and December 2020.
排除标准
- •Patients who have HER2 positive tumors.
结局指标
主要结局
1.To analyze the overall survival (OS) of included patients
时间窗: Post 6 months and 12 months of treatment completion.
2 To analyze the progression-free survival(PFS) of included
时间窗: Post 6 months and 12 months of treatment completion.
patients
时间窗: Post 6 months and 12 months of treatment completion.
次要结局
- To analyze the time-on-treatment of the combination of(chemo and endocrine therapy for included patients)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Tucatinib Together With Pembrolizumab and TrastuzumabHER2-positive Breast CancerBreast CancerNCT04789096Breast Cancer Trials, Australia and New Zealand31
已完成
不适用
An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 YearsBreast CancerNCT01480674Hoffmann-La Roche160
Unknown
1 期
ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)Estrogen Receptor-PositiveHER2-NegativeLocally Advanced Breast CancerMetastatic Breast CancerNCT04669587EnhancedBio USA Inc.106
Unknown
不适用
Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective AnalysisERBB2Metastatic NeoplasmBreast CancerNCT02560311University of Zurich100
招募中
不适用
HER2-positive Breast Cancer RegistryHER2 + Breast CancerNCT06603597Priyanka Sharma1,000